
Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia did not meet its primary …

Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III trials finding it safe and …

GSK has announced today that the first patient has been dosed in part of their Phase III clinical trial investigating …

Takeda has acquired PvP Biologics following the conclusion of a Phase 1 study of the investigational medicine TAK-062 for the …

AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase …

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …

The National Institute for Health Research (NIHR) has released a new whitepaper outlining the substantial benefits NHS High Throughput Centres …

Japanese pharma firm Takeda have announced that lung cancer treatment Alunbrig has proven successful in reducing the risk of disease …

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

AstraZeneca, the Cambridge-based British company, had recruitment for its final stage Phase III trials placed on partial hold. The drug …

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …

Amgen was relying on the results of the trial to justify its $10.4 billion purchase of Onyx Pharmaceuticals, acquiring Kyprolis …

Takeda Pharmaceuticals has announced the initiation of a global Phase III clinical trial to test its live-attenuated tetravalent dengue vaccine …

Roche has presented new Phase III data for cancer immunotherapy Tecentriq (atezolizumab), which shows a clinically meaningful improvement in overall …